Olga Morozova1, Sergii Dvoryak2, Frederick L Altice3. 1. Ukrainian Institute on Public Health Policy, 4 Malopidvalna Str., Office 6, Kyiv 01001, Ukraine; Yale University School of Public Health, 135 College Street, Suite 323, New Haven, CT 06510-2283, USA. 2. Ukrainian Institute on Public Health Policy, 4 Malopidvalna Str., Office 6, Kyiv 01001, Ukraine. Electronic address: dvoryak@uiphp.org.ua. 3. Yale University School of Medicine, New Haven, CT, USA; Yale University School of Public Health, 135 College Street, Suite 323, New Haven, CT 06510-2283, USA.
Abstract
BACKGROUND: Ukraine's volatile syndemics of tuberculosis (TB) and HIV among people who inject drugs (PWIDs) introduces numerous treatment challenges for each condition, including high mortality and development of multi-drug resistant TB (MDR-TB). METHODS: A prospective, non-randomized 90-day observational study was conducted in six Ukrainian TB treatment sites to assess the effectiveness of integrating methadone maintenance (MMT) with TB treatment using: (1) 90-day TB treatment retention; (2) time to treatment discontinuation; (3) TB medication adherence; and (4) subject disposition, including mortality. Of the 110 participants enrolled, 57 received MMT and 53 did not (non-MMT). RESULTS: All of the primary outcomes were significantly better in MMT versus non-MMT groups, including 90-day TB treatment completion (89.5% versus 73.6%; p=0.031), time to TB treatment discontinuation (p=0.039) and TB medication adherence (97.1% versus 86.2%; p<0.001) after controlling for death. The major reasons for treatment non-completion in the non-MMT group included death (N=3), administrative discharge from the clinic (N=5), loss to follow-up (N=2), and arrest (N=4). Overall, 90-day mortality was high (8.2%). After controlling for covariates differing between the two groups at baseline, the only independent predictor of completing 90 days of TB treatment was receipt of MMT in an integrated treatment setting (AOR=3.05; 95% CI 1.08-8.66). CONCLUSIONS: MMT integrated into inpatient TB treatment significantly improves retention in TB treatment and TB medication adherence among PWIDs. These findings call for policy change to increase the number of MMT sites in TB facilities and make MMT a low-threshold treatment option for opioid dependence in Ukraine.
BACKGROUND: Ukraine's volatile syndemics of tuberculosis (TB) and HIV among people who inject drugs (PWIDs) introduces numerous treatment challenges for each condition, including high mortality and development of multi-drug resistant TB (MDR-TB). METHODS: A prospective, non-randomized 90-day observational study was conducted in six Ukrainian TB treatment sites to assess the effectiveness of integrating methadone maintenance (MMT) with TB treatment using: (1) 90-day TB treatment retention; (2) time to treatment discontinuation; (3) TB medication adherence; and (4) subject disposition, including mortality. Of the 110 participants enrolled, 57 received MMT and 53 did not (non-MMT). RESULTS: All of the primary outcomes were significantly better in MMT versus non-MMT groups, including 90-day TB treatment completion (89.5% versus 73.6%; p=0.031), time to TB treatment discontinuation (p=0.039) and TB medication adherence (97.1% versus 86.2%; p<0.001) after controlling for death. The major reasons for treatment non-completion in the non-MMT group included death (N=3), administrative discharge from the clinic (N=5), loss to follow-up (N=2), and arrest (N=4). Overall, 90-day mortality was high (8.2%). After controlling for covariates differing between the two groups at baseline, the only independent predictor of completing 90 days of TB treatment was receipt of MMT in an integrated treatment setting (AOR=3.05; 95% CI 1.08-8.66). CONCLUSIONS:MMT integrated into inpatient TB treatment significantly improves retention in TB treatment and TB medication adherence among PWIDs. These findings call for policy change to increase the number of MMT sites in TB facilities and make MMT a low-threshold treatment option for opioid dependence in Ukraine.
Authors: Steven L Batki; Valerie A Gruber; Julia Moon Bradley; Mark Bradley; Kevin Delucchi Journal: Drug Alcohol Depend Date: 2002-05-01 Impact factor: 4.492
Authors: Alexey Kruk; Wendy Bannister; Daria N Podlekareva; Nelly P Chentsova; Aza G Rakhmanova; Andrzej Horban; Perre Domingo; Amanda Mocroft; Jens D Lundgren; Ole Kirk Journal: AIDS Date: 2011-07-31 Impact factor: 4.177
Authors: Frederick L Altice; R Douglas Bruce; Gregory M Lucas; Paula J Lum; P Todd Korthuis; Timothy P Flanigan; Chinazo O Cunningham; Lynn E Sullivan; Pamela Vergara-Rodriguez; David A Fiellin; Adan Cajina; Michael Botsko; Vijay Nandi; Marc N Gourevitch; Ruth Finkelstein Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: I Dubrovina; K Miskinis; S Lyepshina; Y Yann; H Hoffmann; R Zaleskis; P Nunn; M Zignol Journal: Int J Tuberc Lung Dis Date: 2008-07 Impact factor: 2.373
Authors: Olena Iakunchykova; Anna Meteliuk; Alexei Zelenev; Alyona Mazhnaya; Melissa Tracy; Frederick L Altice Journal: Int J Drug Policy Date: 2018-04-12
Authors: Roman Shrestha; Pramila Karki; Frederick L Altice; Oleksandr Dubov; Liana Fraenkel; Tania Huedo-Medina; Michael Copenhaver Journal: AIDS Behav Date: 2018-04
Authors: A M W Efsen; A Schultze; R F Miller; A Panteleev; A Skrahin; D N Podlekareva; J M Miro; E Girardi; H Furrer; M H Losso; J Toibaro; J A Caylà; A Mocroft; J D Lundgren; F A Post; O Kirk Journal: J Infect Date: 2017-10-20 Impact factor: 6.072